Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial

Diabetes, obesity & metabolism(2023)

引用 1|浏览8
暂无评分
摘要
Jens Christian Laursen has received lecture fees from Boehringer Ingelheim, all fees given to Steno Diabetes Center Copenhagen. Emilie H. Zobel is employed by Novo Nordisk A/S. Adriaan Kooy has received lecture and/or consultancy fees from Bayer, Boehringer Ingelheim, Merck Sharpe and Dohme, Mundipharma and Novo Nordisk, and research grants from Boehringer Ingelheim, Novo Nordisk and ZonMw. Gozewijn D. Laverman has received lecture fees from Sanofi, AstraZeneca, and Janssen, has served as a consultant for Abbvie, Sanofi, Novo Nordisk, AstraZeneca, Boehringer Ingelheim and Merck Sharp & Dohme, and has received research grants from AstraZeneca, Boehringer, NovoNordisk, Lilly and Sanofi. Frederik Persson has served as a consultant, on advisory boards or as an educator for AstraZeneca, Novo Nordisk, Boehringer Ingelheim, Sanofi, Mundipharma, MSD, Novartis and Amgen, and has received research grants to institution from Novo Nordisk, Boehringer Ingelheim, Amgen and AstraZeneca. Hiddo J. L. Heerspink is a consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Eli-Lilly, Gilead, GoldFinch, Janssen, Merck, Mundi Pharma, Mitsubishi Tanabe, Novo Nordisk and Travere Pharmaceuticals. He received research support from Abbvie, AstraZeneca, Boehringer Ingelheim. Janssen and Novo Nordisk. Marie Frimodt-Møller reports having received research grants from Novo Nordisk and speaking fees from Boehringer Ingelheim, Novartis, Baxter and Sanofi. Peter Rossing has received consultancy and/or speaking fees (to his institution) from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, MSD, Mundipharma, Novo Nordisk, Vifor and Sanofi Aventis, holds research grants from AstraZeneca and Novo Nordisk, all fees given to Steno Diabetes Center Copenhagen. Viktor Rotbain Curovic, Marjolein Y. A. M. Kroonen, Niels Jongs and Tine W. Hansen have no competing interests to declare. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15180. Individual, de-identified participant data are not freely available because of the risk of patient re-identification but interested parties can request access to de-identified participant data or anonymized clinical study reports through submission of a request for access to the corresponding author, provided that the necessary data protection agency and ethical committee approvals are provided in compliance with relevant legislation. Appendix S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
更多
查看译文
关键词
clinical trial,diabetes complications,diabetic neuropathy,empagliflozin,linagliptin,SGLT2 inhibitor
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要